- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02332148
Assessment of the Safety and Efficacy of 3VM1001 Cream for Treatment of Chronic Pain Caused by Knee Osteoarthritis.
August 19, 2015 updated by: CDA Research Group, Inc.
A Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 3VM1001 Cream for the Treatment of Chronic Pain Caused by Osteoarthritis of the Knee: A Proof of Concept Study
3VM1001 is a topical cream that may be useful for the treatment of chronic osteoarthritis of the knee.
This proof of concept study is a randomized, placebo-controlled, double-blind study to compare treatment with 3VM1001 cream to an inactive cream placebo.
Subjects will self-treat for 30 days.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
3VM1001 is a topical cream that may be useful for the treatment of chronic osteoarthritis of the knee.
This proof of concept study is a randomized, placebo-controlled, double-blind study to compare treatment with 3VM1001 cream to an inactive cream placebo.
Subjects will self-treat for 30 days with investigational drug or placebo.
Rescue medication with acetaminophen, up to 2g daily, is permitted.
This study is intended to evaluate the safety and efficacy of 3VM1001 topical cream, a copper-containing cream.
Subjects will self treat with drug or placebo three times daily for 30 days.
All subjects will have a total of three visits to the clinic and will complete a daily diary each day for the 30 days of treatment.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Osteoarthritis of the knee according to American College of Rheumatology clinical radiological criteria;
- OA of knee ≥ 6 months prior to screening;
- age 40 years or older;
- subjects of childbearing potential and their partners must use effective contraception;
- women of childbearing age must have a negative pregnancy test or screening or be using an acceptable form of birth control;
- moderate to severe chronic OA pain defined as POM score between 40 mm and 90 mm;
- baseline WOMAC pain subscale score ≥ 9;
- no change in physical activity and/or therapy for the past 3 months;- all concurrent medications taken for any reason stable for 14 days;
- ability to follow protocol with reference to cognitive and situational factors (eg. stable housing, ability to attend visits;
- ability to read and write English;
- ability to apply cream without assistance;
- able to provide written informed consent.
Exclusion Criteria:
- Presence of significant medical disorder that would compromise the participant's safety to take part in the trial (e.g. cancer, immunosuppressed) or evidence of alcohol or substance abuse;
- Wilson's disease or other disorder of copper metabolism
- BMI >35
- Known hypersensitivity or allergy to any component of the product, or to acetaminophen
- Pregnant and breastfeeding women
- Transcutaneous electrical nerve stimulation and use of crutches, walkers, or wheel chairs should be excluded prior to and during treatment
- Active conditions over the area to be treated such as eczema or psoriasis, compromised integrity of the intact, superficial skin layer over the area to be treated.
- Pain in any joint other than the index joint that could interfere with the patient's assessment of pain in the index joint
- Recent injury (traumatic or sports related) to either knee causing pain and interference with daily activities (e.g. walking)
- Recent surgery/procedure to either knee causing pain that could interfere with study assessments of pain, function, and QoL.
- Extreme pain in the target knee characterized by POM score of >90 mm
- Mild pain in the target knee, characterized by POM score of < 40 mm
- Open surgery of the target knee within the last year
- Arthroscopic surgery of the target knee within the last 3 months
Use of prohibited concomitant medications/therapies during the 30-day treatment period including:
- devices or therapeutic treatments for knee pain or ambulation
- analgesics other than acetaminophen
- Systemic corticosteroids
- other investigational drugs
- chemotherapeutic drugs
- immunotherapy
- topical products applied to the target knee
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 3Vm1001
3VM1001 topical cream containing 10 mg/day of copper, for 30 days
|
3VM1001 topical cream for treatment of osteoarthritis of the knee
|
Placebo Comparator: Placebo
Placebo for 3VM1001, topical cream without 3VM1001
|
Topical cream placebo for 3VM1001; cream without 3VM1001
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time-averaged change in pain from baseline in a standard visual analog scale
Time Frame: baseline and 30 days
|
baseline and 30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Anticipated)
October 1, 2015
Study Completion (Anticipated)
March 1, 2016
Study Registration Dates
First Submitted
January 5, 2015
First Submitted That Met QC Criteria
January 5, 2015
First Posted (Estimate)
January 6, 2015
Study Record Updates
Last Update Posted (Estimate)
August 21, 2015
Last Update Submitted That Met QC Criteria
August 19, 2015
Last Verified
August 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3VM0115
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis of Knee
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
CrystalGenomics, Inc.CompletedLocalized Primary Osteoarthritis of Hip | Localized Primary Osteoarthritis of KneeKorea, Republic of
-
zhoupingBeijing Friendship Hospital; Beijing Jishuitan HospitalUnknownOsteoarthritis Of KneeChina
-
Universidade Nova de LisboaHospital de Santa Maria, Portugal; NOVA Medical School; Hospital de Egas Moniz; Instituto de Medicina Molecular João Lobo Antunes and other collaboratorsUnknown
-
Hospices Civils de LyonSmith & Nephew, Inc.Completed
-
First Affiliated Hospital of Harbin Medical UniversityShanghai Baiying Medical Technology Co., Ltd.UnknownOsteoarthritis Of KneeChina
-
Stempeutics Research Pvt LtdStempeutics Research Malaysia SDN BHDCompleted
-
Government Medical College, BhavnagarCompletedOsteoarthritis of Knee JointIndia
-
Ottawa Hospital Research InstituteCompleted
-
GCS Ramsay Santé pour l'Enseignement et la RechercheRecruitingUnilateral Primary Osteoarthritis of KneeFrance
Clinical Trials on 3VM1001
-
CDA Research Group, Inc.CompletedTreatment of PHNUnited States
-
CDA Research Group, Inc.Completed